{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:50:57Z","timestamp":1791323457587,"version":"4.3.1"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaad.2026.09.045","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:51:49Z","timestamp":1789721509000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-5711","authenticated-orcid":false,"given":"Kevin","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Husseinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2026.09.045_bib1","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2026.09.045_bib2","first-page":"21","article-title":"Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","volume":"2021","author":"Costanzo","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.jaad.2026.09.045_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S141235","article-title":"Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes","volume":"10","author":"Sikirica","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"9","key":"10.1016\/j.jaad.2026.09.045_bib4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association between biologics use and risk of serious infection in patients with psoriasis","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2026.09.045_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11926-017-0692-2","article-title":"Cardiometabolic disorders in psoriatic disease","volume":"19","author":"Sobchak","year":"2017","journal-title":"Curr Rheumatol Rep"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226035553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226035553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:06:55Z","timestamp":1791320815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226035553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":5,"alternative-id":["S0190962226035553"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.09.045","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.09.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}